Journal article
Clinical outcomes with utilization of high-potency topical steroids in patients with lichen sclerosus-associated vulvar cancer
Gynecologic oncology, v 187, pp 58-63
01 Aug 2024
PMID: 38733953
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
To evaluate the impact of high-potency topical steroid use on risk of recurrence of lichen sclerosus-associated vulvar cancer.
This is a retrospective cohort study evaluating patients with lichen sclerosus (LS)- associated vulvar squamous cell cancer (VSCC). Demographic and clinical outcome data were compared between two comparison groups: patients who received steroids, mainly clobetasol, and patients who did not receive steroids following treatment of LS-related vulvar cancer. Categorical variables were compared using Fisher's exact test or chi-square test. Continuous variables were compared using a two-sided student's t-test. Time to recurrence (TTR) and overall survival (OS) were analyzed using Kaplan-Meier survival plot and compared using Mantel-Cox log rank test. Cox proportional hazard regression models were conducted to generate hazard ratios for both TTR and OS. A p value of <0.05 was considered statistically significant.
A total of 49 patients were included, with 36 patients receiving steroid treatment and 13 patients in the expectant management group. The median age of diagnosis was 68. The average BMI was 31.7 +/− 7.0. The median length of follow up was 41 months. The majority of patients were diagnosed with stage I VSCC. There was no difference in demographics or oncologic management of vulvar cancer between the two cohorts. Overall recurrence was decreased among patients who received steroid treatment when compared to patients who did not, 12 patients (33.3%) versus 9 patients (69.2%) respectively (p = 0.048).
High-potency topical steroid use following treatment of lichen sclerosus-associated vulvar squamous cell carcinoma is associated with decreased risk of recurrence and prolonged median time to recurrence.
•Lichen sclerosus - associated vulvar cancer carries a worse prognosis when compared with HPV- associated vulvar cancer.•Topical steroids represent standard of care therapy for lichen sclerosus but its impact on vulvar cancer risk is unknown.•High-potency topical steroids may reduce risk of recurrence and prolong recurrence free survival in LS-associated VSCC.
Metrics
4 Record Views
Details
- Title
- Clinical outcomes with utilization of high-potency topical steroids in patients with lichen sclerosus-associated vulvar cancer
- Creators
- Nujsaubnusi C. Vue - Allegheny Health NetworkJessica Sassani - Allegheny Health NetworkBeth Prairie - Allegheny Health NetworkYue Yin - Allegheny-Singer Research InstituteThomas C. Krivak - Allegheny Health NetworkSarah Crafton - Allegheny Health NetworkChristopher Morse - Allegheny Health NetworkJohn Nakayama - Allegheny Health NetworkAlyssa Wield - Allegheny Health NetworkZachary D. Horne - Allegheny Health NetworkEirwen M. Miller - Allegheny Health Network
- Publication Details
- Gynecologic oncology, v 187, pp 58-63
- Publisher
- Elsevier Inc
- Number of pages
- 6
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Obstetrics and Gynecology
- Web of Science ID
- WOS:001325499400001
- Scopus ID
- 2-s2.0-85192463561
- Other Identifier
- 991022135634804721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Obstetrics & Gynecology
- Oncology